Dermatomyositis Plasma

About Dermatomyositis Plasma

Dermatomyositis Plasma for Autoimmune Inflammatory Myopathy Research

Dermatomyositis Plasma is collected from IRB-consented donors clinically diagnosed with dermatomyositis and processed under standardised conditions to preserve autoantibodies, complement components, cytokines, muscle enzymes and metabolites. Dermatomyositis is an autoimmune inflammatory myopathy distinguished from polymyositis by characteristic skin disease — Gottron’s papules and heliotrope rash — and by a perivascular, complement-mediated pattern of injury with prominent capillary involvement. Plasma is acellular and is supplied for soluble-analyte work rather than cell-based assays.

Disease Biology and Why Plasma

• Perivascular, complement-mediated injury: membrane attack complex deposition on capillaries and capillary loss are characteristic of dermatomyositis and distinguish it mechanistically from the endomysial, T-cell-mediated pattern of polymyositis. Plasma preserves complement components and activation products.
• Prominent type I interferon signature: interferon-inducible proteins and chemokines are elevated and track disease activity, making dermatomyositis a leading human model for interferon-targeted therapy.
• Myositis-specific autoantibodies map onto phenotype: anti-MDA5 with clinically amyopathic disease and rapidly progressive interstitial lung disease; anti-TIF1-gamma with malignancy association; anti-Mi-2 with classic skin disease and generally better prognosis; anti-NXP2 and anti-SAE with further distinct presentations.
• Muscle enzymes — creatine kinase and aldolase — are standard plasma-appropriate markers of muscle injury and are used alongside antibody status to characterise donors.
• Skin and vascular biology: the cutaneous disease is intrinsic to dermatomyositis rather than incidental, and circulating mediators support work linking skin, muscle and vascular involvement.
• Interstitial lung disease is a major driver of outcome, particularly in anti-MDA5-positive donors, and can be studied through circulating lung injury and fibrosis markers.

Donor Stratification Available

• Myositis-specific antibody status where available: anti-MDA5, anti-TIF1-gamma, anti-Mi-2, anti-NXP2, anti-SAE
• Myositis-associated antibodies, including anti-Ro52 and anti-synthetase antibodies
• Clinical phenotype: classic dermatomyositis, clinically amyopathic dermatomyositis, or juvenile dermatomyositis
• Presence and severity of interstitial lung disease
• Malignancy-associated disease
• Treatment status: corticosteroids, methotrexate or other conventional immunosuppressants, IVIg, rituximab, JAK inhibitor, or treatment-naive
• Disease activity and muscle enzyme status at collection
• Matched healthy controls available

Product Features

• Research Use Only (RUO)
• Plasma isolated from clinically confirmed dermatomyositis donors
• Rigorous donor screening and sample quality checks
• IRB-approved protocols with documented informed consent
• Standardized collection and processing SOPs
• Suitable for soluble-analyte methods including ELISA, multiplex immunoassay, immunoblot and mass spectrometry
• Standard and custom aliquot volumes available

De-identified Donor Data

• Verified dermatomyositis diagnosis, with diagnosis method where documented
• Age, sex assigned at birth, race/ethnicity
• Medications and disease severity or stage
• Optional: comorbidities, laboratory values, and clinical history
• Additional dermatomyositis-specific metadata available on request

Applications

• Myositis-specific autoantibody detection, titration and multiplex panel development
• Type I interferon signature and interferon-inducible protein measurement
• Complement activation and membrane attack complex product profiling
• Creatine kinase, aldolase and muscle injury marker studies
• Disease activity and treatment response biomarker discovery
• Interstitial lung disease biomarker research, particularly in anti-MDA5-positive donors
• Plasma proteomic and metabolomic discovery studies
• Differential biomarker work separating dermatomyositis from polymyositis and other inflammatory myopathies

Other Dermatomyositis Specimen Types

Dermatomyositis donor material is also available as Dermatomyositis Serum, Dermatomyositis PBMC, Dermatomyositis Whole Blood, Dermatomyositis Leukopak, and Dermatomyositis Skin Punch Biopsy. Cell-based assays such as flow cytometry and immunophenotyping require the PBMC or leukopak products. Related cohorts include Myositis Plasma and Inclusion Body Myositis Plasma.

Compliance and Quality Assurance

• IRB-approved protocols and HIPAA-compliant donor data handling
• Informed donor consent
• Standardized collection and processing SOPs
• Documentation support available for regulatory review

Ordering & Customization

Samples are available in both standard and custom volumes to meet your research needs. For pricing, international shipments, or country-specific documentation requirements, please contact us at learnmore@sanguinebio.com to ensure compliance with your local regulations. To compare collection formats, visit our human plasma page.